New York, NY (PRWEB) July 22, 2013 -- The Mount Sinai Medical Center has named Jean-Frédéric Colombel, MD, as the Director of The Leona M. and Harry B. Helmsley Charitable Trust Inflammatory Bowel Disease Center, which is scheduled to open in 2014. Dr. Colombel also recently joined the faculty of the Icahn School of Medicine at Mount Sinai as Professor of Medicine, Gastroenterology.
“Dr. Colombel is an internationally-renowned clinician and researcher in inflammatory bowel disease and gastroenterology,” said Bruce Sands, MD, Professor of Medicine, Gastroenterology and Chief of the Henry D. Janowitz Division of Gastroenterology at the Icahn School of Medicine. “He will lead a team of clinicians and researchers in a fully integrated, state-of-the-art facility to provide comprehensive IBD diagnostics and treatments for adults and children and to advance translational IBD research.”
Dr. Colombel is best known for his participation in the identification of NOD2 as a susceptibility gene for Crohn’s disease, and the identification of a new subtype of Escherichia coli associated with Crohn’s disease, as well as the development of the Anti-Saccharomyces Cerevisiae Antibody (ASCA) test, which remains the most sensitive and specific marker for Crohn’s disease. He has authored or coauthored more than 500 peer-reviewed articles, books, and book chapters on IBD.
Most recently, he was Professor of Hepatogastroenterology at Centre Hospitalier Universitaire de Lille in Lille, France, and President of the European Crohn’s and Colitis Organization.
The Center will offer patients a collaborative team of experts in gastroenterology, clinical immunology, nutrition, pathology, psychology, radiology, colorectal and laparoscopic surgery, and genetics and genomics. Its Young Adult IBD Transitional Program will assure patients a seamless transition from pediatric to adult gastroenterologists.
The Center’s scientists will conduct genomic, proteomic, metabolomic, and microbiomic research to create disease models that would identify biomarkers for disease type and pathways, with the ultimate goal of developing approaches to disrupt the pathogenesis of the disease and to treat at-risk patients before IBD develops. Mount Sinai’s IBD Registry and Biobank, which analyzes complex data at every stage of a patient’s life, will collaborate to drive this research and expand Mount Sinai’s clinical trial capabilities.
About The Mount Sinai Medical Center
The Mount Sinai Medical Center encompasses both The Mount Sinai Hospital and the Icahn School of Medicine at Mount Sinai. Established in 1968, the Icahn School of Medicine is one of the leading medical schools in the United States, and is noted for innovation in education, biomedical research, clinical care delivery, and local and global community service. It has more than 3,400 faculty in 32 departments and 14 research institutes, and ranks among the top 20 medical schools both in National Institutes of Health (NIH) funding and by U.S. News & World Report.
The Mount Sinai Hospital, founded in 1852, is a 1,171-bed tertiary- and quaternary-care teaching facility and one of the nation's oldest, largest and most-respected voluntary hospitals. In 2012, U.S. News & World Report ranked The Mount Sinai Hospital 14th on its elite Honor Roll of the nation's top hospitals based on reputation, safety, and other patient-care factors. Mount Sinai is one of 12 integrated academic medical centers whose medical school ranks among the top 20 in NIH funding and by U.S. News & World Report and whose hospital is on the U.S. News & World Report Honor Roll. Nearly 60,000 people were treated at Mount Sinai as inpatients last year, and approximately 560,000 outpatient visits took place.
For more information, visit http://www.mountsinai.org.
Mount Sinai Press Office, The Mount Sinai Medical Center, http://icahn.mssm.edu/, 212-241-9200, [email protected]